Camargo

NOVEMBER 11, 2020

Presumably, Antares’ long-established 90-person urology sales force can achieve pull-thru of this drug product. The guidance clarifies the differences between an RLD and an RS for use during in vivo bioequivalence studies to support an ANDA and how the Agency determines the appropriate RS to designate in the Orange Book.

Development 242

Development Bioequivalency Generic Drugs Production 242

Drug Patent Watch

DECEMBER 12, 2024

Market Size and Potential Generic manufacturers are more likely to target drugs with a large market size and high sales volume. Drugs treating common chronic conditions or those with a broad patient base are often prime targets for generic entry. Q: What role do regulatory agencies play in determining the likelihood of generic entry?

Licensing 96

Licensing Licensing Branding Drugs 96

Pharma in Brief

FEBRUARY 8, 2024

For instance, the generic drug must be “the pharmaceutical equivalent of the [CRP]” and be “bioequivalent with the [CRP]”. The Regulations require manufacturers of certain drugs – including prescription drugs – to provide this notice within 30 calendar days after 12 months without sales have passed.

Production 52

Production Generic Drugs Drugs Bioequivalency 52

The Pharma Data

DECEMBER 28, 2020

Amphastar’s newly approved synthetic peptide product was determined by the FDA to be bioequivalent and therapeutically equivalent to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar, which has a recombinant DNA (rDNA)-origin. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid.

Bioequivalency 52

Bioequivalency Production Sales Marketing 52

XTalks

FEBRUARY 8, 2021

Unlike small-molecule generic drugs, biosimilars do not need to demonstrate bioequivalence to the innovator product. MYTH: Clinical pharmacology studies of biosimilars aim to establish safety and effectiveness.

Production 78

Production Insulin Branding Generic Drugs 78

The Pharma Data

AUGUST 5, 2020

There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. J Neurol Sci.

Trials 52

Trials Medicine Production Containment 52

The Pharma Data

MAY 3, 2021

Korea To Toughen Co-Bioequivalence Study System Amid Generic Quality Issue ( Pink Sheet ). Siemens raises outlook as COVID-19 antigen tests blast past original sales target ( MedtechDive ). Siemens raises outlook as COVID-19 antigen tests blast past original sales target ( MedtechDive ).

Gene Therapy 52

Gene Therapy Vaccination Vaccine Bioequivalency 52